Daniel Markowitz
Stock Analyst at Evercore ISI Group
(4.71)
# 156
Out of 5,111 analysts
19
Total ratings
75%
Success rate
22.6%
Average return
Main Sectors:
Stocks Rated by Daniel Markowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Initiates: In-Line | $68 | $66.96 | +1.55% | 1 | Nov 25, 2025 | |
| NTRA Natera | Maintains: Outperform | $190 → $250 | $231.95 | +7.78% | 2 | Nov 7, 2025 | |
| GH Guardant Health | Maintains: Outperform | $68 → $90 | $102.07 | -11.83% | 2 | Oct 30, 2025 | |
| RMBS Rambus | Maintains: Outperform | $114 → $126 | $94.23 | +33.72% | 2 | Oct 28, 2025 | |
| WST West Pharmaceutical Services | Maintains: Outperform | $350 → $390 | $267.56 | +45.76% | 3 | Oct 23, 2025 | |
| TECH Bio-Techne | Maintains: Outperform | $60 → $72 | $58.51 | +23.06% | 2 | Oct 7, 2025 | |
| RGEN Repligen | Maintains: Outperform | $155 → $175 | $157.39 | +11.19% | 4 | Oct 7, 2025 | |
| INSP Inspire Medical Systems | Maintains: Outperform | $150 → $125 | $130.68 | -4.35% | 2 | Oct 7, 2025 | |
| TMDX TransMedics Group | Initiates: Outperform | $155 | $126.79 | +22.25% | 1 | Sep 16, 2025 |
DexCom
Nov 25, 2025
Initiates: In-Line
Price Target: $68
Current: $66.96
Upside: +1.55%
Natera
Nov 7, 2025
Maintains: Outperform
Price Target: $190 → $250
Current: $231.95
Upside: +7.78%
Guardant Health
Oct 30, 2025
Maintains: Outperform
Price Target: $68 → $90
Current: $102.07
Upside: -11.83%
Rambus
Oct 28, 2025
Maintains: Outperform
Price Target: $114 → $126
Current: $94.23
Upside: +33.72%
West Pharmaceutical Services
Oct 23, 2025
Maintains: Outperform
Price Target: $350 → $390
Current: $267.56
Upside: +45.76%
Bio-Techne
Oct 7, 2025
Maintains: Outperform
Price Target: $60 → $72
Current: $58.51
Upside: +23.06%
Repligen
Oct 7, 2025
Maintains: Outperform
Price Target: $155 → $175
Current: $157.39
Upside: +11.19%
Inspire Medical Systems
Oct 7, 2025
Maintains: Outperform
Price Target: $150 → $125
Current: $130.68
Upside: -4.35%
TransMedics Group
Sep 16, 2025
Initiates: Outperform
Price Target: $155
Current: $126.79
Upside: +22.25%